Bristol Myers builds the case for psoriasis hopeful as it waits in regulatory limbo
Bristol Myers Squibb continues to tout more data for its experimental psoriasis drug that it hopes will shake up the market.
The pharmaceutical giant posted two-year results from a long-term extension study of deucravacitinib, showing the drug remained effective after two years. The drug, which analysts predict can bring in billions in sales by 2026, is an oral TYK2 inhibitor for adult patients with moderate to severe plaque psoriasis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.